-
公开(公告)号：US20240287607A1
公开(公告)日：2024-08-29
申请号：US18410314
申请日：2024-01-11
申请人： IMMUNEXPRESS PTY LTD
IPC分类号： C12Q1/6883 , C12Q1/689 , G16B25/00 , G16B25/10
CPC分类号： C12Q1/6883 , C12Q1/689 , G16B25/00 , G16B25/10 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
-
公开(公告)号：US20210139991A1
公开(公告)日：2021-05-13
申请号：US16951758
申请日：2020-11-18
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/6883 , G16B25/00 , C12Q1/689
摘要： Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected or suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
-
公开(公告)号：US10167511B2
公开(公告)日：2019-01-01
申请号：US15201431
申请日：2016-07-02
申请人： ImmuneXpress Pty Ltd
IPC分类号： C07H21/00 , C12Q1/6883 , C12Q1/689 , G06F19/20
摘要： Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
-
公开(公告)号：US20150259746A1
公开(公告)日：2015-09-17
申请号：US14714188
申请日：2015-05-15
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/16 , G16B25/00 , G16B40/00
摘要： The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.
-
5.发明授权公开(公告)号：US12006548B2
公开(公告)日：2024-06-11
申请号：US16951758
申请日：2020-11-18
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/6883 , C12Q1/689 , G16B25/00 , G16B25/10
CPC分类号： C12Q1/6883 , C12Q1/689 , G16B25/00 , G16B25/10 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed is a method for treating or inhibiting the development of severe sepsis in a subject based on measuring the level of a defensin alpha 4 (DEFA4) polynucleotide expression product.
-
公开(公告)号：US20220325348A1
公开(公告)日：2022-10-13
申请号：US17678658
申请日：2022-02-23
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/6883 , G16B25/00 , G16B25/10 , G16B25/20
摘要： The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.
-
公开(公告)号：US20220243272A1
公开(公告)日：2022-08-04
申请号：US17481622
申请日：2021-09-22
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/6883 , G16B25/00 , C12Q1/689 , G16B25/10
摘要： Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected or suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
-
公开(公告)号：US10190169B2
公开(公告)日：2019-01-29
申请号：US14900122
申请日：2014-06-18
申请人： ImmuneXpress Pty Ltd
IPC分类号： C12Q1/6883 , G06F19/20 , C12Q1/689
摘要： Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.
-
公开(公告)号：US20150218640A1
公开(公告)日：2015-08-06
申请号：US14616565
申请日：2015-02-06
申请人： ImmuneXpress Pty Ltd
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/16 , G16B25/00 , G16B40/00
摘要： The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.
摘要翻译： 本发明公开了方法，试剂盒和装置，以及与其相关的试剂和组合物，用于获得用于诊断生物学受试者中至少一种病症的存在，不存在或程度的指标，或者用于预测生物学对象中的至少一种病症 生物科目。 还公开了用于诊断生物受试者中至少一种病症的存在，不存在或程度或用于预测生物受试者中的至少一种病症的生物标志物标志。 本发明还公开了用于鉴定用于生物标志物签名的生物标志物的方法，试剂盒和装置，以及与其相关的试剂和组合物。
-
公开(公告)号：US20240201186A1
公开(公告)日：2024-06-20
申请号：US18596338
申请日：2024-03-05
申请人： ImmuneXpress Pty Ltd
IPC分类号： G01N33/569 , A61B5/00 , C12Q1/6883 , G01N33/574
CPC分类号： G01N33/56911 , A61B5/412 , C12Q1/6883 , G01N33/57484 , C12Q2600/158 , G01N2469/00 , G01N2800/26
摘要： Disclosed are methods, apparatus, kits and compositions for determining the absence of a systemic bacterial infection (sepsis) in patients, particularly ones presenting to hospital emergency departments (ED) as outpatients, by measurement of the host immune response using peripheral blood. The are methods, apparatus, kits and compositions can be used in mammals for diagnosing, making treatment decisions, determining the next procedure or diagnostic test, or management of patients suspected of having an infection, including those presenting with fever or other signs of systemic inflammation. More particularly, peripheral blood RNA and protein biomarkers are disclosed that are useful for distinguishing between the host immune response to bacteria compared to the host immune response to other causes of systemic inflammation including trauma, burns, autoimmune disease, asthma, anaphylaxis, arthritis, obesity and viral infections. As such, the biomarkers are useful for distinguishing bacterial-associated systemic inflammatory response syndrome from non-bacterial systemic inflammation to provide clinicians with strong negative predictive value (>95%) so that sepsis can be excluded as a diagnosis in patients presenting to ED with clinical signs of systemic inflammation.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.044 秒)
